The dysplastic nevus is a discreet histologic entity that exhibits some clinical and histologic features overlapping with common nevi and melanoma. These overlapping features present a therapeutic challenge, and with a lack of accepted guidelines, the management of dysplastic nevi remains a controversial subject. Although some differences between dysplastic and common nevi can be detected at the molecular level, there are currently no established markers to predict biologic behavior. In part II of this continuing medical education article, we will review the molecular aspects of dysplastic nevi and their therapeutic implications. Our goal is to provide the clinician with an up-to-date understanding of this entity to facilitate clinical management of patients with nevi that have histologic dysplasia. ( J Am Acad Dermatol 2012;67:19.e1-12.)
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LACK OF PREDICTIVE MARKERS AND GUIDELINES FOR DYSPLASTIC NEVI Key points
d Dysplastic nevi have overlapping features with common nevi and melanoma d There is a lack of consensus or guidelines for management
The dysplastic nevus (DN) is a distinct histologic entity (see part I of this continuing medical education article). Nevertheless, DN share some histologic features of nondysplastic or ''common'' nevi (CN), including the presence of neoplastic nests of melanocytes, and features of melanoma such as cytologic atypia and dermal inflammatory response. 1 The benign lesions (DN and CN) cannot be distinguished from each other based on clinical examination alone, 2, 3 and DN often have some clinical features associated with melanoma, such as an irregular border and the asymmetric distribution of pigmentation. 4, 5 Given these considerations, this review will focus on studies based on lesions that have been defined histologically.
A conference among melanoma thought leaders, convened at the National Institutes of Health in 1992, sought to define the histologic basis of ''early'' melanoma and DN. 6 Changes in terminology were recommended-which have not been widely adoptedbut guidelines for the clinical management of DN lesions were never issued. The ''consensus conference'' yielded no consensus. [7] [8] [9] [10] [11] A decade later, there remained a lack of consensus among dermatologists in the management of patients with DN and the need for reexcision of DN after biopsy. 12 With the passing of yet another decade, it now seems timely to reassess the collective clinical experience and incorporate new molecular insights concerning DN. It is our hope that an informative review of all the evidence may lead the way to a consensus regarding the management of DN. It is possible that molecular analyses of these melanocytic lesions will identify differences between DN, CN, and melanoma that may prove useful in predicting their biologic behavior. The first step is to characterize panels of lesions with defined histologic patterns at a molecular level to identify candidate markers. Second, candidate markers must be analyzed in panels of lesions with a known clinical outcome in order to develop hypotheses regarding the predictive value of particular markers. Finally, a blinded trial is necessary to validate such moleculareclinical associations. The detection of specific chromosomal gains/losses by fluorescence-based in situ hybridization to differentiate Spitz 14, 15 and mitotically active nevi 16 from melanoma is a paradigm for this approach.
MOLECULAR ASPECTS OF DYSPLATIC NEVI
A number of studies have investigated DN at a molecular level, and similarities and differences between DN, CN, and melanoma are summarized in Table I .
Clonal origin of dysplastic nevi Key point d Studies of clonality in dysplastic nevi are limited, but suggest that dysplastic nevi, like most common nevi, are clonal
Although several studies have shown that most nevi are clonal neoplasms (ie, arising from a single melanocyte) based on pattern of X chromosome inactivation in tissues from female patients, most were limited to the study of CN, and only one of these included DN. Robinson et al 17 reported evidence for clonality in 81% of nevi, 25% of which were DN. They found no correlation between the presence or absence of dysplasia and clonality. The demonstration of clonality, however, may not be informative as to whether DN arise de novo or from a preexisting CN, because in both circumstances all of the cells would be expected to have arisen from a single progenitor cell. Given the heterogeneity of dysplasia observed within DN, 18 it seems possible that some DN may arise within CN.
Molecular profiling
Key point d Although many differences are apparent from molecular profiling, their clinical significance is unknown
Scatolini et al 19 isolated RNA from 18 CN, 11 DN, and 23 melanomas representing the radial and vertical growth phases and examined global gene expression using whole genome microarrays. Expression patterns among DN were very similar with respect to genes involved in ectodermal development, while a greater heterogeneity of expression was seen among genes involved in mitosis, apoptosis, and the regulation of transcription. Many similarities were seen between DN and CN, in particular the expression of genes involved in mitosis, apoptosis, and transcriptional regulation. Some proliferation genes, however, were expressed at higher levels in DN than in CN. Expression patterns of a group of genes involved in cellular detoxification, RNA processing, and antigen presentation allowed separation of DN into two subclasses: one more similar to radial growth melanoma and with expression levels higher than CN, and the other similar to vertical growth melanoma and with expression levels lower than CN.
Mutations in BRAF and Ras Key point d Dysplastic nevi harbor mutations in BRAF comparable to common nevi, but Ras mutations are rare
The activation of the Ras/mitogen-activated protein kinase (MAPK) pathway is predominant in melanoma, and approximately 60% of tumors express a ''driver mutation'' in the BRAF kinase (most commonly V600E) that may potentiate Ras signaling 20 and appears to be a useful therapeutic target in metastatic melanoma. 21 The BRAF mutation is also predominant in nevi, 22 and several studies have examined its prevalence in DN. Wu 24 These studies indicate that the presence of BRAF mutation does not appear to be a molecular factor distinguishing DN from CN.
In contrast to congenital nevi, which commonly harbor Ras mutations, 25 two studies performed by Papp et al 26, 27 indicate that Ras mutations are rarely present in DN. They found activating N-ras mutations in only 1 of 19 26 and 1 of 18 27 DN examined.
Mutations and expression of tumor suppressor genes Key points d Compared to common nevi, some dysplastic nevi exhibit alterations in p16 or p53 expression d Phosphatase and tensin homolog expression is lost in a fraction of dysplastic and common nevi
As noted above, the p16 tumor suppressor is a major melanoma predisposition gene that is commonly mutated in families with inherited melanoma. The p16 protein is a critical negative regulator of the cell cycle, and its functional loss is common in tumors. 28 A role for p16 in proliferative arrest of nevi is supported by the common finding of large atypical nevi in patients with germline p16 mutations. 29 No differences in clinical or histologic presentation of nevi, however, were noted in comparing individuals with different p16 mutations. 30 Several studies have investigated the presence of somatic p16 mutations in nevi, including DN. Wang et al 31 found no p16 mutations in 20 nevi examined (six of which were DN). Similarly, Papp et al 26 found no p16 mutations among 19 DN. By contrast, Lee et al 32 found four p16 mutations (three missense and one intronic) in 3 of 12 DN. Interestingly, three of these mutations were cytosine: thymine transitions at dipyrimidine sequences, which is characteristic of mutations directly induced by ultraviolet light. 33 Therefore, p16 mutations appear to be rare in nevi, but an insufficient number of nevi have been examined to ascertain whether the incidence is increased in DN compared to CN. On the other hand, p16 expression in some DN may be compromised by gene deletion (discussed below).
Mutations in p53, which is upregulated by DNA damage signaling and promotes apoptosis, are found in more than 50% of cancers and to a lesser extent in melanoma. 34 Several studies have investigated the presence of p53 mutations in DN. Lee et al 32 found two p53 missense mutations in 12 DN examined. In another study, Levin et al 35 detected p53 mutations in two of five DN and 2 of 11 CN. On the other hand, Papp et al 26 failed to identify p53 mutations in 19 DN studied. Several groups have also examined p53 expression in DN by immunohistochemistry, as a method to detect p53 mutations that increase protein stability. The p53 protein has generally not been observed in CN or DN, 36, 37 although McGregor et al 38 found p53 to be present in a minority of DN but not in CN. Similarly, two subsequent studies found that p53 protein expression was increased in DN compared to CN. 29, 39 These immunohistochemical-based studies, however, are problematic because of a variance in sensitivity of detection and the lack of direct confirmation of p53 mutations.
The phosphatase and tensin homolog (PTEN) phosphatase functions as a tumor suppressor through the inhibition of phosphatidylinositol kinase signaling, resulting in diminished activation of the survival kinase Akt, and is frequently lost in tumors. 40 Several studies have evaluated the expression of PTEN in panels of melanomas and nevi. Expression of PTEN appears to be retained in most (approximately 60-70%) nevi and absent in most melanomas; significant differences between DN and CN were not observed.
41,42
Microsatellite instability and allelic loss of tumor suppressors Key points d Microsatellite instability may be seen in some melanomas and dysplastic nevi, but not common nevi d Some dysplastic nevi may harbor deletions in the p16-encoding chromosomal region 9p21
It is important to note that the lack of detection of mutations in a gene is not synonymous with the presence of the gene and/or expression of wild-type protein. This is because deletions may occur in one allele (hemizygous deletion, referred to as loss of heterozygosity [LOH] ) that will not be detected by polymerase chain reactionebased sequencing methods. In the context of LOH, mutation or loss of the remaining allele results in loss of function or complete absence of the protein, which in the case of a tumor suppressor may promote transformation. Historically, LOH of particular alleles was determined by assessing the presence or absence of markers (microsatellites) associated with particular genetic loci. Variation in microsatellites, referred to as microsatellite instability, often occurs in chromosomal regions containing tumor suppressor genes, and is a common feature of tumors (including melanoma). Hussein et al 43 found microsatellite instability at chromosomal regions 1p and 9p in DN and melanomas, but not in CN; the overall prevalence of microsatellite instability was 31% (7/22) in melanomas, 28% (17/60) in DN, and 0% (0/30) in CN. This result is consistent with a previous report by Boni et al 44 revealing allelic losses at 1p in three of nine DN and at 9q in one of nine DN. Bale et al 45 mapped a ''DN locus'' to a region on chromosome 1, and this was confirmed in subsequent linkage studies. 46 ,47 A more recent genome-wide association study identified variants at 9p21 and 22q13 associated with nevus development, 48 although it is not clear if either set of variants favors development of DN over CN.
Multiple additional studies have documented LOH in melanomas involving the region 9p21 that contains the p16 gene locus, 49, 50 and some studies have shown increased LOH in DN compared to CN. Park et al 51 reported LOH in seven of nine DN at one or more loci within 9p21, while LOH was not detected in any of the 13 CN studied. Tran 51 have also shown LOH for the p53-containing locus in 43% (3/7) of DN; interestingly, these three lesions also revealed LOH for 9p21.
These early studies assessed the presence of the p16-containing locus using various microsatellite markers as noted above, which may account for some of the variability and may overestimate loss of the p16 gene. More recent studies have used fluorescence in situ hybridization using sequencespecific probes to directly detect loss of particular genes. Using this approach, Sini 29 although an earlier study found comparable levels of p16 in DN and CN. 53 Proliferation markers Key point d Dysplastic nevi may exhibit higher proliferative rates than common nevi but lower than melanoma
The observation of dark dots by dermoscopy at the periphery of some DN, as noted above, suggests that these nevi may be in the process of active proliferation. 54 Several studies have investigated whether DN have higher rates of proliferation compared to CN. Lebe et al 55 examined a panel of melanomas and nevi by immunohistochemistry using antibodies against cyclin D1 and Ki-67 to identify proliferating cells. While melanomas had much higher rates of proliferation than nevi, an analysis of 42 DN and 21 CN revealed comparable rates of cyclin D1 expression but significantly higher rates of Ki-67 positivity in DN compared to CN. In a related study examining expression of cyclins D1 and D3, Alekseenko et al 56 found significant differences between DN and CN. They reported mean rates of 8% for melanoma (n = 14), 5% for DN (n = 24), and 0.3% for CN (n = 10) for cyclin D1, and rates of 18% for melanoma, 6% for DN, and 2% for CN for cyclin D3. These findings are consistent with the higher expression of proliferative genes in DN compared to CN, as reported by Scatolini et al. 19 On the other hand, Nasr et al 57 did not observe positive staining for Ki-67 or phosphorylated histone H3 in any lesions among a panel of 20 DN and 20 CN. These studies are limited by sensitivity of the staining and the markers examined, but taken together, it appears that DN may be associated with higher rates of proliferation than CN, although all nevi are generally less proliferative than melanomas.
Apoptosis markers
Key point d Lack of evidence that dysplastic nevi cells are more resistant to apoptosis than those in common
nevi
One explanation for the long-term persistence of nevi is that nevomelanocytes are more resistant to apoptosis than nonenevus-associated melanocytes, and this has been shown in vitro. 58 There is no evidence, however, that cells comprising DN are more resistant to apoptosis than cells of CN based on the expression of apoptotic regulatory molecules. Expression of the prototypic apoptosis inhibitor Bcl-2 did not appear significantly different between DN and CN in two studies, 39, 59 although Tron et al 60 reported Bcl-2 expression in CN (5/7) but not DN (0/ 6). The inhibitor of apoptosis protein Survivin is broadly expressed in nevi, with no significant differences noted between DN and CN. 61, 62 Similarly, the expression of various death receptors that trigger extrinsic apoptotic pathways was comparable in DN and CN. 63 Finally, Zhang et al 64 reported that the tumor suppressor RUNX3, a regulator of apoptosis and proliferation, is expressed in equal proportions of DN (34/63; 54%) and CN (14/25; 56%).
Increased reactive oxygen species in dysplastic nevi Key point d Dysplastic nevi may display higher levels of oxidative stress than common nevi
Pavel et al 65 analyzed melanocytes from DN and found elevated levels of reactive oxygen species compared to CN. Similarly, Smit et al 66 isolated melanocytes from DN lesions and adjacent skin, and found that DN-associated melanocytes exhibited higher levels of reactive oxygen species and oxidative DNA damage than normal melanocytes from the same patients. The role of oxidative stress in the development and potential progression of DN has not been investigated. A current model to explain nevus development and transformation to melanoma invokes the concept of senescence or terminal growth arrest. 67 It is thought that nevi initially result from melanocyte proliferation followed by a senescent state; failure of some cells within a nevus to achieve (or escape of some cells from) senescence may lead to melanoma. In this model, the initial hyperproliferation and subsequent induction of senescence is mediated by activation of an oncogene (such as mutant BRAF), and the senescent state is maintained by expression of p16, which is sufficient to mediate senescence in some tumor cells in culture. 68 Consistent with this model, expression of mutant (V600E) BRAF in human melanocytes triggers cell growth followed by growth arrest, and some nevi express markers of senescence, such as p16 and acidic beta-galactosidase. 29, 69 It has been debated, however, whether acidic beta-galactosidase represents a reliable marker of senescence and whether nevi are truly senescent, given that nevus-derived cells can proliferate in vitro. [70] [71] [72] [73] There are obviously additional limitations to the senescence model, given that some nevi do not express mutant BRAF, and the majority of melanomas do not arise directly from nevi (see below). Nevertheless, it would be interesting to investigate the expression of senescence markers in DN compared to CN. Bennett 74 initially proposed that DN might represent escape from p16-dependent senescence, and her group subsequently found that p16 expression was reduced in DN, 29 but studies 29, 69 examining other senescence-associated markers in nevi did not include DN. Mutant active BRAF induces senescence by upregulating the tumor suppressor insulin-like growth factorebinding protein 7 (IGFBP7), which acts through autocrine/paracrine pathways to inhibit MAPK signaling, and IGFBP7 is frequently lost in melanoma. 75, 76 Several studies have examined the link between mutant BRAF and IGFBP7 in DN. Decarlo 
Markers of senescence

MANAGEMENT OF DYSPLASTIC NEVI
Variation in management of dysplastic nevi by dermatologists Key points d There is significant variation in practice indicated by survey d There is a lack of evidence supporting routine ophthalmologic examinations for patients with dysplastic nevi
As noted above, no guidelines regarding the management of DN emanated from the NIH conference in 1992, 6, 79 and none have been forthcoming since. In a survey of fellows of the American Academy of Dermatology regarding the management of patients with a history of histologically confirmed DN, Tripp et al 12 found significant variation in physician practices. While 99% of the dermatologists recommended that these patients perform self-examinations of their skin, 75% performed total body skin examinations on follow-up visits, 60% recommended ophthalmologic examinations for some patients, 49% obtained baseline total body skin photography for most patients, and 23% routinely used dermoscopy. 12 Regarding follow-up visits for their patients with DN, 58% recommended examinations every 12 months and 33% recommended examinations every 6 months in most patients. Variation in surgical management of DN is discussed below.
While there is clear evidence that the use of photography and dermoscopy can enhance early melanoma detection, their use is largely dependent on physician familiarity and training in these techniques and economic feasibility of their incorporation into individual practices. 80 Is there evidence to inform as to the indication for ophthalmologic examinations-notably, does a patient history of DN portend the future risk of developing ocular melanoma? Vink et al 81 described five melanoma kindreds, each with a single member affected by ocular melanoma, suggesting an association between cutaneous and ocular melanoma. On the other hand, Molven et al 82 described a family with inherited melanoma based on CDK4 (R24H) mutation and a single member who developed ocular melanoma, but the patient was not a mutation carrier, suggesting a different etiology for the ocular and cutaneous melanomas in this family. In a more definitive study, Taylor et al 83 found no association among 44 patients between uveal melanoma and cutaneous melanoma and/or DN. They found a 4.5% prevalence of DN in patients with uveal melanoma compared to a 41% prevalence of DN in patients with cutaneous melanoma. 83 Patients with DN therefore do not appear to have an increased risk for ocular melanoma, and ophthalmologic screening in the absence of ocular symptoms may not be indicated. There were no obvious clinical changes in the size and morphology of the study nevi, but 4 of 14 treated nevi and none of 14 untreated nevi showed significant reduction of junctional and intraepidermal nevomelanocytes and papillary dermal fibrosis with variable inflammation suggestive of partial regression. Somani et al 85 conducted a more limited trial of 5% imiquimod in which three patients applied imiquimod to a single clinically atypical nevus five nights per week for 12 weeks. Biopsy specimens of the nevi were obtained at the outset of the study, and these nevi were excised after the treatment period. None of the lesions cleared; two proved to be DN and developed inflammatory reactions while the third lesion was a CN that demonstrated minimal inflammation. The authors were concerned that the two DN appeared to display more severe histologic atypia after imiquimod treatment. 85 Although systemic 5-fluorouracil (5-FU) has been associated with eruptive DN (see above), topical application of 5-FU has been investigated as a potential therapeutic for DN. Bondi et al 86 treated six DN in a 37-year-old woman with 5% 5-FU cream twice daily for 5 weeks; four CN from unrelated individuals were also treated. All six DN responded J AM ACAD DERMATOL VOLUME 67, NUMBER 1 with inflammation, ulceration, and subsequent (clinical) disappearance of the lesion, while the four control CN remained unchanged. 86 Subsequent patch tests and intradermal skin testing in the patient who responded had no evidence of contact sensitivity to 5-FU. 86 The authors noted that an additional four DN lesions in this patient responded to 5-FU, while those in additional patients did not. It does not appear that the response of DN to 5-FU has been evaluated in any subsequent studies in the literature.
The effect of topical tretinoin under occlusion with and without topical steroid was investigated by Stam-Posthuma et al 87 in a prospective randomized, double blind study. Three clinically atypical nevi in 30 patients were treated under Actiderm occlusion (Actiderm Cosmaceuticals, New York, NY, replaced weekly for 4 months) either with placebo, 0.1% tretinoin, or tretinoin in combination with 1% hydrocortisone. Lesions were monitored by photography throughout the study period and histologically at the end of the study, revealing that although about 40% of lesions treated with tretinoin or tretinoin plus hydrocortisone were reduced in size, they remained clinically atypical and retained histologic atypia. 87 Edwards et al 88 treated eight patients with DNS with oral isotretinoin, 40 mg twice a day for 4 months. At the completion of therapy, at least three previously identified and photographed clinically atypical lesions were rephotographed and removed for histologic evaluation. There were no clinical or histologic changes observed in the lesions, which were confirmed to be DN in these patients. Oral isotretinoin does not appear to have a significant biologic effect on DN.
Finally, laser ablation has been attempted for the removal of DN. Duke et al 89 treated 31 nevi (including DN) with a Q-switched ruby laser (694 nm, 40-60 nanoseconds, 7.5-8.0 J per cm 2 ) and reported that although 16 (52%) of the nevi had a clinically visible decrease in pigment at the 4-week follow-up visit, no lesion showed complete histologic removal of all nevomelanocytes. A potential concern is that laser treatment of nevi may increase the risk of malignancy by eliminating the protective pigment, thereby leaving the remaining cells more vulnerable to ultraviolet light radiation and potentially obscuring the ability to detect morphologic changes over time. However, to our knowledge, there have been no reports of malignancies arising in laser-treated nevi. 90 Prophylactic surgical removal Key point d There is a lack of evidence that prophylactic removal of clinically atypical nevi reduces melanoma risk
In patients with numerous or clinically atypical nevi, there may be a tendency to remove lesions in a ''prophylactic'' manner. Such practice of nevus removal may be sought by the patient to reduce their melanoma risk, or promulgated by the physician out of fear of missing a melanoma. It is clear that complete removal of a patient's nevi will not prevent melanoma, which (as discussed above) is more likely to arise from isolated epidermal melanocytes in the skin than from preexisting nevi. However, it is unclear to what extent ''molectomy,'' however impractical this might be, would reduce long-term melanoma risk in high-risk patients. A report of one such case in a patient with history of multiple melanomas described the removal of 117 clinically atypical lesions over a 1-year period. The patient developed no subsequent melanomas, 91 but to our knowledge this approach has not been formally studied. 12 found that 86% of dermatologists intend on biopsy to remove DN completely, 75% use margins of $ 2 mm, and 67% would reexcise DN with positive histologic margins. Although the NIH Consensus Conference 6,79 established margin guidelines (2-5 mm) for the reexcision of DN, indications for reexcision were not specified. Because DN often consist of melanocytes that extend beyond the clinical lesion, it is common for biopsy specimens (even when physician intent is to completely remove the lesion) to have positive margins. The decision to reexcise versus observe likely relates to a variation in physician perception of DN and the risk of transformation to melanoma.
Reexcision controversy
A recent study 92 surveyed 101 dermatologists in the Chicago area regarding the role of histologic grade and margin status documented in the pathology report in their decision to reexcise or observe DN after biopsy. Positive margin status was correlated with higher rates of decision to reexcise for all grades of nevi, but was most marked for lesions diagnosed with ''moderate'' dysplasia. While 81% of respondents indicated they would reexcise nevi with moderate dysplasia and positive margins on biopsy, only 9% of respondents favored the reexcision of moderately dysplastic lesions with negative margins.
There appear to be three primary reasons for reexcising DN. First, there may be concern that a particular lesion is melanoma, based on physician-or patient-related factors or the histologic results. As noted above, there is discordance among dermatopathologists as to identification of dysplasia and cytologic atypia, [93] [94] [95] and therefore lesions with severe dysplasia could represent melanoma. It is therefore recommended that lesions with severe histologic atypia be reexcised. Lesions with only mild or moderate histologic atypia are a source of much greater controversy. A second reason to reexcise DN is to prevent their recurrence. This reason may in part be seated in a fear that the lesion may recur as melanoma (thinking that if DN are precursors of melanoma then they should be completely removed). However, given that the risk of melanoma arising in DN may be no greater than in CN (as discussed in part I of this review), following this course may lead one to reexcise all nevi with positive margins. In addition, one may want to avoid lesions recurring as ''pseudomelanoma''-a benign histologic simulator of melanoma 96 that can be problematic for pathologists. Another potential concern is overdiagnosis of a recurrent DN as melanoma if the pathologist signing out the recurrent lesion has no knowledge of the previous pathology. Reexcising DN for these reasons may represent a form of defensive medicine driven by medicolegal concerns, but there also may be an implicit financial incentive to perform additional procedures. What may be perceived as an increasing tendency to over-biopsy and overtreat DN has been referred to in the lay press as the ''nevomelanocytic industrial complex.'' 97 The risks and benefits of reexcising DN are summarized in Table II. Some of these concerns have been informed by two recent studies. First, King et al 98 analyzed clinical findings and histologic changes in 357 cases (28% were DN) of recurrent nevus phenomenon that were compared with 34 cases of melanoma with regression. Most recurrences were in patients under 40 years of age, and located on the back, with a median recurrence time of 5 months. Many cases revealed only pigment, and residual nevus was present in only 33% of cases, often associated with deeper adnexal structures. While many recurrent nevi shared some histologic similarities (ie, pseudomelanoma) with primary melanoma with scar/fibrosis, the vast majority of recurrent nevi were readily identifiable. 98 Second, Goodson et al 99 studied the rate of clinical recurrence and factors associated with recurrence of DN after biopsy. Of 195 DN with more than 2 years of follow-up, seven (3.6%) demonstrated recurrence on clinical examination. In all, 98 DN had a follow-up period of at least 4 years with no clinical recurrence. Of 61 CN biopsy sites examined, clinical recurrence was observed in two (3.3%). For all nevi studied, recurrence was significantly associated with shave biopsy technique but not with nevus dysplasia or subtype, or the presence of positive margin or congenital features. This study suggests that the reexcision of nevi-including mildly to moderately DN with a positive histologic margin-may not be necessary.
CONCLUSION AND RECOMMENDATIONS
There is considerable variation among physicians in their clinical approach to patients with DN, which likely stems from different interpretations of the DN and its relative risk of transformation to melanoma. Studies in recent years have identified some biologic and molecular similarities between DN and CN, as well as differences (Table I) . Despite these distinctions, including an increased proliferative rate, genomic instability, and the loss of p16 in some DN, in general DN are far more similar to CN than to melanoma (Table III) . We look forward to future studies that may identify subsets of DN, based on molecular markers, that could be associated with higher risk. At present, however, there is no clinical evidence that DN as a group behave more aggressively (ie, a tendency toward melanoma transformation) than CN, and no markers have been validated to identify those lesions (either DN or CN) that may be more predisposed to melanoma transformation and/or metastasis.
If individual DN lesions can be distinguished from melanoma histologically, then such lesions appear to represent a variant of melanocytic nevus, and given their prevalence could be considered a normal nevus variant (such as blue nevus, Spitz nevus, etc). Just as DN represent a particular nevus subtype to which particular individuals are predisposed, similar findings have more recently been extended to patients with distinct subtypes of CN. 100, 101 These observations support a broader concept of melanocytic tumor formation, in which all melanocytes within an individual are genetically similar and the nevi that ultimately are formed are a product of a specific set of genetic defects and environmental exposures.
Given these considerations, we suggest that most DN can be managed clinically like CN. That is to say, any clinically suspicious lesions should be removed and those patients with clinically atypical or numerous nevi should be carefully monitored given their increased melanoma risk. A complete summary of our recommendations for management of DN is provided in Table IV . 
